Filing Analysis
Vanda Pharmaceuticals Inc. filed an 8-K to announce the release of its quarterly earnings results for the period ended June 30, 2026. The company is holding a conference call to discuss these financial results and operational updates.
📋 Key Facts
- Report date: August 5, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes an announcement of an earnings press release (Exhibit 99.1)
- A conference call is scheduled to discuss results of operations and financial condition.
Vanda Pharmaceuticals Inc. announced that the U.S. FDA has approved NEREUS (tradipitant) for the prevention of vomiting induced by motion. This is a positive regulatory development regarding their product pipeline.
📋 Key Facts
- FDA approval granted for NEREUS (tradipitant).
- Indication: Prevention of vomiting induced by motion.
- Announcement date: December 30, 2025.
Vanda Pharmaceuticals Inc. announced that the FDA has lifted a partial clinical hold on its drug candidate, tradipitant, intended for the treatment of motion sickness.
📋 Key Facts
- FDA has lifted the partial clinical hold on tradipitant.
- Tradipitant is being developed for the treatment of motion sickness.
- Announcement made via press release on December 4, 2025.
Vanda Pharmaceuticals Inc. issued an 8-K to provide a regulatory update regarding its drug candidate, tradipitant, intended for the treatment of motion sickness.
📋 Key Facts
- Filing date: November 28, 2025
- Subject matter: Regulatory update on tradipitant (motion sickness treatment)
- The filing incorporates a press release as Exhibit 99.1
Vanda Pharmaceuticals Inc. announced its intent to issue a press release and hold a conference call on October 29, 2025, regarding its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is an announcement of upcoming quarterly earnings results (Q3 2025).
- Earnings call scheduled for October 29, 2025.
- Reporting period: Quarter ended September 30, 2025.
Vanda Pharmaceuticals announced a collaborative framework with the FDA to resolve disputes concerning its drugs HETLIOZ (tasimelteon) and tradipitant. This indicates progress in regulatory negotiations but acknowledges prior friction or legal/regulatory challenges.
🚩 Red Flags
- Existence of 'disputes' with the FDA suggests previous regulatory hurdles or non-compliance issues that could impact product commercialization or market access.
📋 Key Facts
- Date of event: October 1, 2025
- The company reached a collaborative framework with the U.S. FDA.
- The resolution concerns disputes regarding HETLIOZ (tasimelteon) and tradipitant.
Vanda Pharmaceuticals Inc. filed an 8-K to announce the release of its quarterly results for the period ended June 30, 2025, and a corresponding earnings conference call.
📋 Key Facts
- The filing relates to the announcement of results of operations and financial condition for the quarter ended June 30, 2025.
- A press release containing the full text of the results is attached as Exhibit 99.1.
- The company scheduled an earnings conference call to discuss these results on July 31, 2025.
Vanda Pharmaceuticals Inc. held its 2025 annual meeting of stockholders on June 5, 2025. The filing reports the results of shareholder votes regarding director elections, auditor ratification, executive compensation (Say-on-Pay), and amendments to the company's equity incentive plan.
📋 Key Facts
- Annual Meeting held on June 5, 2025.
- Quorum reached with 46,577,816 shares (approx. 79.0%) of the 58,933,982 total shares entitled to vote represented.
- Stephen Ray Mitchell and Tage Honoré were elected as Class I directors for terms ending in 2028.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Shareholders approved an amendment to the 2016 Equity Incentive Plan to increase authorized shares and eliminate its term.
Vanda Pharmaceuticals Inc. filed an 8-K to announce the release of its quarterly earnings results for the period ended March 31, 2025.
📋 Key Facts
- The company issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2025.
- A conference call was scheduled to discuss the quarterly results on May 7, 2025.
- The filing includes standard forward-looking statement cautionary language regarding clinical development and regulatory timelines.
Vanda Pharmaceuticals announced via social media that the FDA has accepted its New Drug Application (NDA) for tradipitant to treat motion sickness. The FDA has set a PDUFA target action date of December 30, 2025.
🚩 Red Flags
- Management is using highly unprofessional/aggressive language regarding regulatory bodies ('broken, unaccountable FDA', 'unfairly and irresponsibly stifles innovation').
- The company is publicly complaining about a standard PDUFA timeline (10 months), suggesting potential frustration with capital runway or investor expectations.
📋 Key Facts
- FDA accepted filing for tradipitant NDA for motion sickness treatment.
- PDUFA target decision date is set for December 30, 2025.
- Clinical data cited: Tradipitant (170mg) showed a vomiting rate of 14.6% vs. 41.2% for placebo (p<0.0001).
- Clinical data cited: Tradipitant (85mg) showed a vomiting rate of 18.9% vs. 41.2% for placebo (p<0.0001).
- The company used aggressive language in its social media post, criticizing the FDA's review timeline.
Vanda Pharmaceuticals announced that its Compensation Committee has approved 2024 performance bonuses and set the 2025 base salaries, bonus targets, and RSU awards for named executive officers.
🚩 Red Flags
- High cash bonus amounts for executives ($947k for CEO) in a micro-cap context may be scrutinized if not tied to clear performance metrics (though the filing mentions 'performance' as the basis).
📋 Key Facts
- CEO Mihael Polymeropoulos awarded a $947,928 bonus for the 2024 period.
- The Compensation Committee approved 2025 annual base salaries for all named executives, ranging from $559,935 to $579,600.
- Restricted Stock Unit (RSU) awards were granted to all five named executive officers, with vesting scheduled in four equal annual installments starting March 1, 2026.
- The compensation review was supported by an analysis from Willis Towers Watson.
Vanda Pharmaceuticals Inc. filed an 8-K to announce the release of its financial results for the quarter and full year ended December 31, 2024. The company is holding a conference call to discuss these results.
📋 Key Facts
- Reporting period: Quarter and Full Year ended December 31, 2024.
- Filing date: February 13, 2025.
- The filing includes an announcement of a press release (Exhibit 99.1) regarding results of operations and financial condition.
Vanda Pharmaceuticals issued a Regulation FD disclosure regarding a social media post on X (formerly Twitter). The post announced the filing of a new drug application (NDA) for tradipitant, intended for the treatment of motion sickness.
📋 Key Facts
- Date of event: January 25, 2025
- Company filed an NDA for tradipitant to treat motion sickness.
- The disclosure was made via a social media post on X (formerly Twitter).
- Information is furnished under Item 7.01 and not considered 'filed' for purposes of Section 18 liability.
Vanda Pharmaceuticals Inc. filed an 8-K to announce the release of its quarterly earnings results for the period ended September 30, 2024.
📋 Key Facts
- The company issued a press release regarding results of operations and financial condition on November 6, 2024.
- A conference call was held to discuss the Q3 2024 earnings results.
- The filing includes Exhibit 99.1 containing the full text of the press release.
Vanda Pharmaceuticals Inc. announced that its Board of Directors has decided not to pursue an unsolicited acquisition proposal from Cycle Group Holdings Ltd. The Board determined the terms were economically identical to a previous offer and concluded that pursuing it was not in the company's best interest.
🚩 Red Flags
- Rejection of an acquisition proposal can sometimes lead to increased volatility or hostile takeover attempts, though no such threat is explicitly stated here.
📋 Key Facts
- Unsolicited acquisition proposal received from Cycle Group Holdings Ltd.
- The terms of the current proposal were 'economically identical' to an earlier proposal from the same entity.
- Board of Directors, after consulting legal and financial advisors, decided not to pursue the offer on October 14, 2024.
- The decision was made based on fiduciary duties.
Vanda Pharmaceuticals Inc. announced that its Board of Directors approved an amendment and restatement of the company's bylaws on October 2, 2024. The changes primarily focus on clarifying procedures for stockholder meetings, director nominations, proxy solicitation, and officer designations.
🚩 Red Flags
- None identified; the filing describes standard administrative/governance updates.
📋 Key Facts
- Board approval date: October 2, 2024
- Amendment includes clarification of business scope at special stockholder meetings
- Modifies disclosure requirements for stockholder-nominated directors under 'advance notice' provisions
- Clarifies adjournment processes for remote communication during technical failures
- Establishes that employees without officer status cannot be deemed officers solely based on job titles
- Specifies that a majority of directors in office may call special Board meetings
Vanda Pharmaceuticals Inc. filed an 8-K to provide a status update regarding its tradipitant development program via a press release.
📋 Key Facts
- The filing was made on September 19, 2024.
- The primary content is an update on the 'tradipitant' development program.
- The update was communicated through a press release attached as Exhibit 99.1.
Vanda Pharmaceuticals Inc. entered into Amendment No. 2 to its existing Rights Agreement with Equiniti Trust Company, LLC on August 7, 2024. The amendment focuses on clarifying definitions related to 'Acquiring Person', 'Acting in Concert', and 'Beneficial Owner'.
🚩 Red Flags
- The existence of a Rights Agreement (Poison Pill) suggests the company is actively defending against potential hostile takeovers or unsolicited acquisitions.
📋 Key Facts
- Amendment No. 2 to the Rights Agreement was executed on August 7, 2024.
- The agreement is with Equiniti Trust Company, LLC acting as rights agent.
- Changes include punctuation corrections to 'Acquiring Person' and restated definitions for 'Acting in Concert' and 'Beneficial Owner'.
- This follows previous amendments dated April 17, 2024, and May 3, 2024.
Vanda Pharmaceuticals Inc. filed an 8-K to announce the release of its quarterly earnings results for the period ended June 30, 2024.
📋 Key Facts
- The company issued a press release regarding its results of operations and financial condition on July 31, 2024.
- A conference call was held to discuss the quarterly earnings results.
- The filing includes forward-looking statements regarding commercial products and clinical development timelines.
Vanda Pharmaceuticals Inc. announced that its Board of Directors has rejected unsolicited acquisition proposals from two entities, Future Pak, LLC and Cycle Group Holdings Ltd. The decision was made following consultation with independent financial and legal advisors.
🚩 Red Flags
- Presence of unsolicited acquisition bids often indicates market perception of undervaluation or potential for hostile takeover activity/activist intervention.
📋 Key Facts
- Date of event: June 19, 2024
- Unsolicited bidders identified: Future Pak, LLC and Cycle Group Holdings Ltd.
- Board action: Rejected both acquisition proposals.
- Advisory involvement: Board consulted with independent financial and legal advisors before the decision.
Vanda Pharmaceuticals Inc. confirmed the receipt of a revised unsolicited, non-binding acquisition proposal from Future Pak, LLC on June 13, 2024.
🚩 Red Flags
- Unsolicited nature of the bid can lead to significant volatility and management distraction.
📋 Key Facts
- Received a revised unsolicited takeover proposal from Future Pak, LLC.
- The proposal is currently classified as 'non-binding'.
- The filing confirms the receipt of the proposal via an attached press release (Exhibit 99.1).
Vanda Pharmaceuticals Inc. confirmed receipt of an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. on June 6, 2024.
🚩 Red Flags
- Unsolicited bids can sometimes indicate market volatility or potential takeover defense scenarios, though this specific notice is neutral/informational.
📋 Key Facts
- Received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd.
- The interest expressed is currently non-binding and does not constitute a formal offer to acquire the company.
- Filing was made under Item 7.01 (Regulation FD Disclosure) rather than a material definitive agreement.
Vanda Pharmaceuticals Inc. filed an amendment to its 8-K to disclose that the Board of Directors has unanimously rejected the conditional resignation of director Phaedra S. Chrousos. Ms. Chrousos had tendered her resignation after receiving less than a majority of votes in the 2024 annual meeting, primarily due to proxy advisory firm recommendations regarding a recent Rights Agreement.
🚩 Red Flags
- Proxy advisory firm recommendation against a director due to governance/rights agreement issues.
- Director received less than a majority of votes cast in the annual meeting.
📋 Key Facts
- The Board unanimously voted on May 22, 2024, to decline Ms. Chrousos' conditional resignation.
- Ms. Chrousos will continue her service as a director until the 2027 annual meeting or until a successor is elected.
- The failed re-election was linked to proxy advisory firm recommendations regarding a Rights Agreement adopted on April 17, 2024.
- The Board's decision to retain Ms. Chrousos was based on her qualifications, the small margin of the vote, and support from the company's largest stockholder.
Vanda Pharmaceuticals Inc. announced that its Board of Directors has rejected a revised, unsolicited acquisition proposal from Future Pak, LLC. The decision was made following consultation with independent financial and legal advisors.
🚩 Red Flags
- Unsolicited nature of the bid suggests potential volatility or disagreement regarding company valuation/strategy.
📋 Key Facts
- Date of event: May 24, 2024
- The Board of Directors rejected a revised, unsolicited acquisition proposal.
- The offeror is identified as Future Pak, LLC.
- The decision was made in consultation with independent financial and legal advisors.
Vanda Pharmaceuticals held its 2024 annual meeting of stockholders where a director's re-election failed to receive a majority of votes, leading to her tendered resignation. The failure was linked to proxy advisory firm recommendations regarding a recent Rights Agreement.
🚩 Red Flags
- Director resignation following failed election (governance instability).
- Proxy advisory firm recommendation against a director due to a Rights Agreement entered into on April 17, 2024.
- Potential for further board/management turnover if the resignation is accepted.
📋 Key Facts
- Annual Meeting held on May 17, 2024.
- Phaedra S. Chrousos failed to receive a majority of votes cast for her election to the Board.
- Ms. Chrousos has tendered her resignation as a result of the vote outcome.
- The Nominating/Corporate Governance Committee is reviewing whether to accept or reject the resignation.
- PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2024.
- Stockholders approved an amendment to increase shares authorized under the 2016 Equity Incentive Plan.
Vanda Pharmaceuticals Inc. filed an 8-K to announce the release of its quarterly earnings results for the period ended March 31, 2024.
📋 Key Facts
- The company issued a press release regarding results of operations and financial condition for the quarter ended March 31, 2024.
- A conference call was held on May 8, 2024, to discuss these results.
- The filing includes standard forward-looking statement disclaimers regarding clinical development and commercial potential.
Vanda Pharmaceuticals Inc. announced on May 7, 2024, that it has received a revised, unsolicited acquisition proposal from Future Pak, LLC.
📋 Key Facts
- Received an unsolicited acquisition proposal from Future Pak, LLC.
- The proposal is described as 'revised', implying prior communication or negotiations.
- Filing date: May 7, 2024.
Vanda Pharmaceuticals entered into an amendment to its existing Rights Agreement with Equiniti Trust Company, LLC. The amendment specifically modifies the definition of 'Exempt Person' to include BlackRock, Inc. and its various investment funds/accounts.
🚩 Red Flags
- Potential for future dilution/control shifts if BlackRock crosses the 20% threshold, though currently managed via the 'Exempt Person' designation.
📋 Key Facts
- Amendment No. 1 to the Rights Agreement was executed on May 3, 2024.
- BlackRock, Inc. and its subsidiaries are now classified as 'Exempt Persons' under the agreement.
- The exemption for BlackRock Investors is contingent: they cease to be an 'Exempt Person' if they acquire 20% or more beneficial ownership of Vanda's common stock.
- The Board retains sole discretion to revoke the exempt status if any representations or warranties are breached.
Vanda Pharmaceuticals has implemented a shareholder rights plan (poison pill) in response to an unsolicited acquisition proposal from Future Pak, LLC (an affiliate of Woodward Pharma Services, LLC). The plan is designed to prevent any entity from acquiring more than 10% of the company's common stock without Board approval.
🚩 Red Flags
- Implementation of a 'poison pill' (shareholder rights plan) indicates an active hostile takeover defense scenario.
- The presence of an unsolicited acquisition attempt suggests significant volatility and potential for sudden changes in corporate control or structure.
- Potential for massive dilution to any entity attempting a rapid accumulation of shares.
📋 Key Facts
- Board authorized a dividend distribution of one Right for each outstanding share of Common Stock on April 17, 2024.
- Record date for Rights distribution is April 29, 2024.
- The trigger event occurs if an 'Acquiring Person' obtains beneficial ownership of 10% or more of the Common Stock.
- Rights allow holders to purchase one-thousandth of a share of Series A Junior Participating Preferred Stock at $25.00 per Right (subject to adjustment).
- The plan includes 'Flip-In' and 'Flip-Over' provisions that significantly dilute an acquiring person's interest if they reach the 10% threshold.
- Unsolicited proposal was received from Future Pak, LLC on April 1, 2024.
Vanda Pharmaceuticals announced that the U.S. FDA has approved Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
📋 Key Facts
- FDA approval granted for Fanapt (iloperidone).
- Indication: Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
- Announcement date: April 2, 2024.
Vanda Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its supplemental New Drug Application for HETLIOZ in treating insomnia. This indicates the FDA does not currently intend to approve the application in its present form.
🚩 Red Flags
- FDA rejection/delay via CRL for a key product indication
- Potential impact on future revenue streams and clinical development costs
📋 Key Facts
- Date of event: March 6, 2024
- Product involved: HETLIOZ (supplemental NDA)
- Indication: Treatment of insomnia
- Regulatory action: Received a Complete Response Letter (CRL) from the FDA
Vanda Pharmaceuticals announced the approval of 2023 annual bonuses and the setting of 2024 base salaries and bonus targets for its named executive officers. The filing also details the granting of Restricted Stock Unit (RSU) awards to these executives.
🚩 Red Flags
- None identified; this is a routine compensation disclosure.
📋 Key Facts
- The Compensation Committee awarded 2023 performance bonuses, including $983,112 to CEO Mihael Polymeropoulos and $294,071 to CFO Kevin Moran.
- 2024 base salaries were approved, ranging from $541,000 for the CFO/SVP level to $933,000 for the CEO.
- RSU awards were granted to all named executive officers, with vesting scheduled in four equal annual installments starting March 1, 2025.
- Compensation analysis was conducted by Willis Towers Watson.
This 8-K/A is an amendment to a previous filing regarding Vanda Pharmaceuticals' acquisition of the U.S. and Canadian rights for PONVORY (ponesimod) from Janssen (a Johnson & Johnson company). The purpose of this specific filing is to provide the required financial statements and pro forma information that were omitted in the original December 7, 2023 report.
🚩 Red Flags
- The filing is an amendment (8-K/A) due to a failure to include required Item 9.01 financial statements in the original disclosure, indicating a procedural oversight or delay in reporting completeness.
📋 Key Facts
- Acquisition target: U.S. and Canadian rights for PONVORY (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen/Johnson & Johnson).
- Filing is an Amendment (8-K/A) to the original report filed on December 7, 2023.
- Includes audited special purpose abbreviated financial statements for the years ended January 1, 2023 and January 2, 2022.
- Includes unaudited special purpose abbreviated financial statements for the nine months ended October 1, 2023 and October 2, 2022.
- Provides unaudited pro forma condensed combined financial information as of December 31, 2023, reflecting the impact of the acquisition.
Vanda Pharmaceuticals Inc. filed an 8-K to announce the release of its financial results for the quarter and full year ended December 31, 2023.
📋 Key Facts
- The filing is related to Item 2.02 (Results of Operations and Financial Condition).
- Reporting period covers the quarter and full year ended December 31, 2023.
- A press release containing the financial results was issued on February 7, 2024.
- The company held/is holding a conference call to discuss these results.
Vanda Pharmaceuticals issued an 8-K to provide a status update regarding the FDA's review of its supplemental New Drug Application (sNDA) for HETLIOZ in treating insomnia.
📋 Key Facts
- Filing date: February 5, 2024
- Subject matter: Update on FDA review status for HETLIOZ sNDA
- Indication: Treatment of insomnia
- The filing incorporates a press release as Exhibit 99.1